SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive: Another in vitro study from Nies and colleagues clearly demonstrated that the uptake and the cytotoxic effect of imatinib in CML cell lines and patients’ leukemic cells were independent from the SLC22A1 expression [76].